altimmune glp 1 Pemvidutide Altimmune's CEO Vipin Garg discusses
Pay in 4 interest-free payments of $5.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Live Spec
Altimmune's CEO Vipin Garg discusses the company's work in MASH with the GLP 1 glucagon dual agonist, pemvidutide Altimmune, Inc. We're excited to share positive 48 week topline results from our IMPACT Phase 2b trial evaluating our investigational glucagon GLP 1 dual receptor agonist in MASH. Read more about this milestone and our unique dual action Altimmune rises as GLP 1 GIP drug curbs heavy drinking in mid stage study BioSpace How Altimmune Could Grab a Big Chunk of the GLP 1 Market The Globe and Mail
Store: larengifo.com · Domain: larengifo.com


























